Co-combination of islets with bone marrow mesenchymal stem cells promotes angiogenesis

详细信息    查看全文

• 作者：Xian-kui Cao^a ; Rui Li^b ; Wei Sun^a ; Yang Ge^a ; Bao-lin Liu^a ; ^{baolinb@163.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Type 1 diabetes mellitus ; Mesenchymal stem cell ; Islet transplantation ; Islet graft revascularization
• 刊名：Biomedicine & Pharmacotherapy
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：78
• 期：Complete
• 页码：156-164
• 全文大小：2690 K

文摘

Islet transplantation is a commonly therapeutic strategy for diabetes mellitus. However, avascular phase and the poor formation of blood vessels in the late period lead to islet allograft loss which contributed to inefficiency and short-acting of islet transplantation. Recently, to speed up new angiogenesis and increase the density of blood vessels around transplanted islets became the hotspot in research of islet transplantation.

Methods

In this study, we undergone co-combination transplantation of allogeneic islet and bone marrow mesenchymal stem cells (BM-MSCs) into non-obese diabetic (NOD) mice and investigated the influence of BM-MSCs in transplanted islet function and neovascularization.

Results

In mice of co-combination transplantation of islet with BM-MSCs, level of blood glucose was improved compared with only BM-MSCs transplanted mice; proliferation of islet cell was enhanced while apoptosis of islet cell was reduced; 2, 4, and 8 weeks post transplantation, peripheral vascular density of islet grafts were significantly more than the islet transplantation group alone; donor lymphocytic chimerism in graft was increased. In result of immunofluorescence analysis, we observed that BM-MSCs can migrate to transplanted islet, differentiate into vascular smooth muscle cells (VSMC) and vascular endothelial cells (VEC), and also secrete vascular endothelial growth factor (VEGF).

Conclusion

BM-MSCs can migrate to transplanted islet and promote neovascularization. Also, it enhanced allograft immune tolerance of islet grafts via increasing donor lymphocytic chimerism.